Abstract
The cell and gene therapy industry’s push to resolve major bottlenecks in both manufacturing capacity and raw materials shortages has kept the build versus buy conversation center stage. It is vital that cell therapy developers and their investors revisit their manufacturing strategy, assess the pros and cons, and design new models to make these life-changing therapies a reality. Here, Dr Rupa Pike discusses the key considerations related to developing a strategic approach to cell therapy manufacturing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
